In stable MS patients, stopping Ocrevus does not seem to increase the risk of disease activity or disability progression for ...
People with late-onset MS, who experience their first symptoms after age 50, tend to have faster disability progression, ...
Fred D. Lublin, MD, discusses evolving concepts in MS, including earlier high-efficacy therapy, unrecognized progression, and ...
Depression screening predicts subsequent disability progression in people with primary progressive multiple sclerosis.
BUFFALO, N.Y. – In recent years, researchers studying multiple sclerosis have concluded that white matter lesion volume in the brain, long considered the best way to monitor MS disease progression, ...
A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.
RMAT designation is based on promising Phase 2 clinical data demonstrating NG01’s potential to reduce disability and ...
Iron dysregulation contributes to MS progression through oxidative stress, ferroptosis, and immune activation, affecting neuronal and immune cell function. Both iron overload and deficiency exacerbate ...
Grace Miller was a 24-year-old law school student when she was diagnosed with multiple sclerosis ...
A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results